NCT03219450 — Dana-Farber Cancer Institute neoantigen vaccine trial
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Registry record
| Registry ID | NCT03219450 ↗ |
|---|---|
| Lead sponsor | Dana-Farber Cancer Institute |
| Collaborators | Oncovir, Inc., BioNTech SE, Merck Sharp & Dohme LLC |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Lymphocytic Leukemia |
| Enrollment | 15 participants (target) |
| Start date | 2021-08-18 |
| Primary completion | 2027-07-31 (est.) |
| Last registry update | 28 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03219450), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03219450?
NCT03219450 (A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.) is registered on ClinicalTrials.gov as Phase 1, sponsored by Dana-Farber Cancer Institute.
Is NCT03219450 recruiting?
As of the 2026-05-28 registry update, NCT03219450 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03219450?
The lead sponsor is Dana-Farber Cancer Institute. Collaborators: Oncovir, Inc., BioNTech SE, Merck Sharp & Dohme LLC.
What condition does NCT03219450 study?
The registered condition is Lymphocytic Leukemia. Primary completion is listed as 2027-07-31 (estimated).
Are results available for NCT03219450?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03219450.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.